Overview

Fluvoxamine for Long COVID

Status:
Recruiting

Trial end date:
2025-05-15

Target enrollment:

Participant gender:

Summary

This clinical trial aims to test the effects of fluvoxamine as a treatment for Long COVID. Fluvoxamine is an FDA approved SSRI for Obsessive Compulsive Disorder (OCD), that has already had success in preventing hospitalization in patients with COVID-19 (STOP COVID and TOGETHER trials). This trial is testing whether fluoxamine helps to improve symptoms and the negative impacts of long COVID.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Washington University School of Medicine

Collaborator:

Balvi COVID Fund

Treatments:

Fluvoxamine